Novo Nordisk's $2.1B Wager on a World Without Needles

The Danish drugmaker turns to an MIT spinout's AI platform in its push to move biologics beyond the needle

6 Mar 2026

Novo Nordisk has agreed to pay up to $2.1bn to license oral drug-delivery technology from Vivtex Corporation, a Boston-based biotechnology company spun out of the Massachusetts Institute of Technology. The deal underlines the Danish group's conviction that the future of obesity and diabetes treatment lies in tablets, not syringes.

Under terms announced on February 25, Vivtex will receive upfront payments, research funding and milestone fees, alongside royalties on future product sales. Novo Nordisk assumes responsibility for all clinical development, regulatory submissions and global commercialisation.

Vivtex was co-founded in 2018 by MIT scientist Robert Langer. The company has developed a robotics-driven screening system called GI-ORIS that uses intact human gastrointestinal tissue to test thousands of drug formulation combinations daily. Artificial intelligence tools then pinpoint the most promising approaches for delivering peptide and protein medicines through the gut wall, a challenge that has long vexed pharmaceutical researchers.

"This agreement sees Boston-based Vivtex license its proprietary oral drug-delivery technologies to the Danish pharmaceutical company," the companies said. Novo Nordisk has positioned the partnership as central to its next phase of oral peptide development.

The group already sells the only approved oral GLP-1 therapy for type 2 diabetes and has recently launched an oral version of its obesity treatment. The Vivtex deal is designed to push bioavailability, the share of a drug that reaches the bloodstream, considerably further. Higher bioavailability would permit lower doses, potentially cutting costs and side effects.

Competition in oral biologics is intensifying. Several rivals are working to convert widely used injectable treatments into pill form.

The broader significance may extend well beyond metabolic disease. Should the platform succeed in clinical trials, it could open a route to oral versions of injectable therapies for autoimmune disorders, cardiovascular disease and other conditions.

Whether the technology can clear the scientific and regulatory barriers that have stalled previous oral biologics efforts is uncertain. The scale of Novo Nordisk's commitment, however, leaves little doubt about where the company believes the industry is heading.